![](/wp-content/uploads/2022/06/June-22-2022-Blast-Cover.png)
$599
Novo and Echosens Partnership to Increase NASH Awareness; GlucoTrack to Initiate First In-human Clinical Study for GlucoTrack 2.0
Two cardiometabolic-related news items have been observed: Novo Nordisk and Echosens announced a partnership to increase awareness and advance early diagnosis of NASH; and GlucoTrack, formerly known as Integrity Applications, provided development updates on its Gen 2 non-invasive glucose monitor (press release). Below, FENIX provides highlights and insights for the respective new items.